On February 4th 2026, Davipharm – a member of Adamed Group marked the opening of the High-Potency R&D Formulation Laboratory at the factory (HCMC).

This milestone highlights the expansion of the company’s R&D capabilities for high-potent drug development, with a strong focus on employee safety and quality.

The lab will be used for early-phase formulation and optimization of highly active products, enabling R&D activities in a controlled environment.

Congratulations on an important step forward in Davipharm’s journey to responsibly develop high-potent drugs and strengthen our R&D infrastructure!